Abstract:BackgroundTanshinone IIA (TIIA) is a diterpene quinone extracted from the plant Danshen (Salvia miltiorrhiza) used in traditional Chinese herbal medicine. It has been reported to have anti-tumor potential against several kinds of cancer, including gastric cancer. In most solid tumors, a metabolic switch to glucose is a hallmark of cancer cells, which do this to provide nutrients for cell proliferation. However, the mechanism associated with glucose metabolism by which TIIA acts on gastric cancer cells remains to be elucidated.ResultsWe found that TIIA treatment is able to significantly inhibit cell growth and the proliferation of gastric cancer in a dose-dependent manner. Using next-generation sequencing-based RNA-seq transcriptomics and quantitative proteomics-isobaric tags for relative and absolute quantification (iTRAQ), we characterized the mechanism of TIIA regulation in gastric cancer cell line AGS. In total, 16,603 unique transcripts and 102 proteins were identified. After enrichment analysis, we found that TIIA regulated genes are involved in carbohydrate metabolism, the cell cycle, apoptosis, DNA damage and cytoskeleton reorganization. Our proteomics data revealed the downregulation of intracellular ATP levels, glucose-6-phosphate isomerase and L-lactate dehydrogenase B chains by TIIA, which might work with disorders of glucose metabolism and extracellular lactate levels to suppress cell proliferation. The up-regulation of p53 and down-regulation of AKT was shown in TIIA- treated cells, which indicates the transformation of oncogenes. Severe DNA damage, cell cycle arrest at the G2/M transition and apoptosis with cytoskeleton reorganization were detected in TIIA-treated gastric cancer cells.ConclusionsCombining transcriptomics and proteomics results, we propose that TIIA treatment could lead cell stresses, including nutrient deficiency and DNA damage, by inhibiting the glucose metabolism of cancer cells. This study provides an insight into how the TIIA regulatory metabolism in gastric cancer cells suppresses cell growth, and may help improve the development of cancer therapy.

Tanshinone IIA Reverses the Malignant Phenotype of SGC7901 Gastric Cancer Cells

[A Study on Anticancer Activity of Tanshinone II A Against Human Breast Cancer].

[A Study on the Effect of Tanshinone II A Against Human Breast Cancer in Vivo].

Integrating transcriptomics and proteomics to show that tanshinone IIA suppresses cell growth by blocking glucose metabolism in gastric cancer cells

Tanshinone IIA Protects Against Methylglyoxal-Induced Injury in Human Brain Microvascular Endothelial Cells.

Tanshinone IIA suppresses ovarian cancer growth through inhibiting malignant properties and angiogenesis

Tanshinones Inhibit the Growth of Multiple Gastric Cancer Cells via Inactivation of PDK1

Tanshinone IIA: New Perspective on the Anti-Tumor Mechanism of A Traditional Natural Medicine.

Tanshinone IIA inhibits gastric cancer cell stemness through inducing ferroptosis

Tanshinone I induces apoptosis and pro-survival autophagy in gastric cancers

Tanshinone IIA reverses gefitinib resistance in EGFR‐mutant lung cancer via inhibition of SREBP1‐mediated lipogenesis

The antitumor natural product tanshinone IIA inhibits protein kinase C and acts synergistically with 17-AAG

Tanshinone IIA: A Review of its Anticancer Effects

Tanshinone IIA activates calcium-dependent apoptosis signaling pathway in human hepatoma cells

Study on the Antitumor Mechanism of Tanshinone IIA In Vivo and In Vitro through the Regulation of PERK-ATF4-HSPA5 Pathway-Mediated Ferroptosis

Tanshinone IIA inhibits leukemia THP-1 cell growth by induction of apoptosis

Tanshinone IIA targeting cell signaling pathways: a plausible paradigm for cancer therapy

Tanshinone IIA affects the malignant growth of Cholangiocarcinoma cells by inhibiting the PI3K-Akt-mTOR pathway

Tanshinone IIA Inhibits Epithelial-to-Mesenchymal Transition Through Hindering β-Arrestin1 Mediated β-Catenin Signaling Pathway in Colorectal Cancer

Tanshinone IIA suppresses gastric cancer cell proliferation and migration by downregulation of FOXM1